Phentolamine

In men undergoing diagnostic and therapeutic intracavernosal injection with phentolamine, robust penile erection was often achieved, but systemic adverse events such as transient hypotension, tachycardia, and dizziness occurred in a subset of otherwise healthy participants, underscoring the need for medical supervision due to cardiovascular risks.

In six healthy volunteers and six hypertensive patients, a 5 mg intravenous bolus of phentolamine produced a rapid fall in systemic vascular resistance and arterial blood pressure, accompanied by increased heart rate and cardiac output and a transient reduction in oxygen uptake, indicating potent vasodilatory and hemodynamic effects even in healthy subjects.

In normal male volunteers, intravenous phentolamine produced marked decreases in arterial blood pressure and systemic vascular resistance with compensatory increases in heart rate and cardiac output; some subjects experienced symptomatic hypotension and tachycardia, illustrating clinically relevant cardiovascular side effects in otherwise healthy individuals.

In adult men with erectile dysfunction and generally preserved cardiovascular health, oral phentolamine (Vasomax) improved erectile function compared with placebo but was associated with increased rates of flushing, nasal congestion, tachycardia, and dizziness, indicating both pro-erectile efficacy and notable vasodilatory side effects.

In men undergoing diagnostic and therapeutic intracavernosal injection with phentolamine, robust penile erection was often achieved, but systemic adverse events such as transient hypotension, tachycardia, and dizziness occurred in a subset of otherwise healthy participants, underscoring the need for medical supervision due to cardiovascular risks.

In human and rabbit corpus cavernosum tissue, phentolamine demonstrated high-affinity binding to alpha-1 and alpha-2 adrenergic receptors and produced concentration-dependent relaxation of pre-contracted erectile tissue, with effective concentrations similar to plasma levels measured in healthy men 30 minutes after a 40 mg oral dose, supporting its mechanism in erectile physiology.

In adult men with erectile dysfunction and generally preserved cardiovascular health, oral phentolamine (Vasomax) improved erectile function compared with placebo but was associated with increased rates of flushing, nasal congestion, tachycardia, and dizziness, indicating both pro-erectile efficacy and notable vasodilatory side effects.

In normal male volunteers, intravenous phentolamine produced marked decreases in arterial blood pressure and systemic vascular resistance with compensatory increases in heart rate and cardiac output; some subjects experienced symptomatic hypotension and tachycardia, illustrating clinically relevant cardiovascular side effects in otherwise healthy individuals.

In six healthy volunteers and six hypertensive patients, a 5 mg intravenous bolus of phentolamine produced a rapid fall in systemic vascular resistance and arterial blood pressure, accompanied by increased heart rate and cardiac output and a transient reduction in oxygen uptake, indicating potent vasodilatory and hemodynamic effects even in healthy subjects.

In men undergoing diagnostic and therapeutic intracavernosal injection with phentolamine, robust penile erection was often achieved, but systemic adverse events such as transient hypotension, tachycardia, and dizziness occurred in a subset of otherwise healthy participants, underscoring the need for medical supervision due to cardiovascular risks.

In adult men with erectile dysfunction and generally preserved cardiovascular health, oral phentolamine (Vasomax) improved erectile function compared with placebo but was associated with increased rates of flushing, nasal congestion, tachycardia, and dizziness, indicating both pro-erectile efficacy and notable vasodilatory side effects.

In normal male volunteers, intravenous phentolamine produced marked decreases in arterial blood pressure and systemic vascular resistance with compensatory increases in heart rate and cardiac output; some subjects experienced symptomatic hypotension and tachycardia, illustrating clinically relevant cardiovascular side effects in otherwise healthy individuals.

In six healthy volunteers and six hypertensive patients, a 5 mg intravenous bolus of phentolamine produced a rapid fall in systemic vascular resistance and arterial blood pressure, accompanied by increased heart rate and cardiac output and a transient reduction in oxygen uptake, indicating potent vasodilatory and hemodynamic effects even in healthy subjects.

In men undergoing diagnostic and therapeutic intracavernosal injection with phentolamine, robust penile erection was often achieved, but systemic adverse events such as transient hypotension, tachycardia, and dizziness occurred in a subset of otherwise healthy participants, underscoring the need for medical supervision due to cardiovascular risks.

In adult men with erectile dysfunction and generally preserved cardiovascular health, oral phentolamine (Vasomax) improved erectile function compared with placebo but was associated with increased rates of flushing, nasal congestion, tachycardia, and dizziness, indicating both pro-erectile efficacy and notable vasodilatory side effects.

In normal male volunteers, intravenous phentolamine produced marked decreases in arterial blood pressure and systemic vascular resistance with compensatory increases in heart rate and cardiac output; some subjects experienced symptomatic hypotension and tachycardia, illustrating clinically relevant cardiovascular side effects in otherwise healthy individuals.

In six healthy volunteers and six hypertensive patients, a 5 mg intravenous bolus of phentolamine produced a rapid fall in systemic vascular resistance and arterial blood pressure, accompanied by increased heart rate and cardiac output and a transient reduction in oxygen uptake, indicating potent vasodilatory and hemodynamic effects even in healthy subjects.

In men undergoing diagnostic and therapeutic intracavernosal injection with phentolamine, robust penile erection was often achieved, but systemic adverse events such as transient hypotension, tachycardia, and dizziness occurred in a subset of otherwise healthy participants, underscoring the need for medical supervision due to cardiovascular risks.

In six healthy volunteers and six hypertensive patients, a 5 mg intravenous bolus of phentolamine produced a rapid fall in systemic vascular resistance and arterial blood pressure, accompanied by increased heart rate and cardiac output and a transient reduction in oxygen uptake, indicating potent vasodilatory and hemodynamic effects even in healthy subjects.

In adult men with erectile dysfunction and generally preserved cardiovascular health, oral phentolamine (Vasomax) improved erectile function compared with placebo but was associated with increased rates of flushing, nasal congestion, tachycardia, and dizziness, indicating both pro-erectile efficacy and notable vasodilatory side effects.

In adult men with erectile dysfunction and generally preserved cardiovascular health, oral phentolamine (Vasomax) improved erectile function compared with placebo but was associated with increased rates of flushing, nasal congestion, tachycardia, and dizziness, indicating both pro-erectile efficacy and notable vasodilatory side effects.

In adult men with erectile dysfunction and generally preserved cardiovascular health, oral phentolamine (Vasomax) improved erectile function compared with placebo but was associated with increased rates of flushing, nasal congestion, tachycardia, and dizziness, indicating both pro-erectile efficacy and notable vasodilatory side effects.

In adult men with erectile dysfunction and generally preserved cardiovascular health, oral phentolamine (Vasomax) improved erectile function compared with placebo but was associated with increased rates of flushing, nasal congestion, tachycardia, and dizziness, indicating both pro-erectile efficacy and notable vasodilatory side effects.